Does the NHS Think Patients Are Imagining Benefits from Cannabis?

Since the rescheduling of cannabis-based products for medicinal use in 2018, many patients and advocates have eagerly anticipated easier access through the NHS. Yet, years later, thousands of individuals who report benefits from cannabis remain frustrated at what feels like cautious or even reluctant prescribing. This post cuts through the policy fog to explain why NHS prescribing remains limited, how that relates (or doesn't) to patients' experiences, and what you actually need to know about medical cannabis access in the UK.

What Changed in 2018? The Rescheduling of Cannabis-Based Products

In November 2018, cannabis-based products moved from a Schedule 1 classification (meaning "no recognised medical use and a high potential for abuse") to Schedule 2 under the Misuse of Drugs Regulations. In plain English: cannabis extracts and some cannabis-derived medicines became legally prescribable by UK doctors, subject to certain conditions.

This legal shift was very significant—it opened the door for patients with certain conditions to access cannabis-based treatments prescribed on the NHS. Before this, even specialist doctors couldn’t legally prescribe medical cannabis; patients were effectively barred from NHS options and forced into private pathways or self-medication, which carried legal risks.

What Did the 2018 Rescheduling Actually Change?

Allowed specialist doctors to prescribe cannabis-based products medically.
Allowed NHS formularies to include cannabis-based medicines where evidence and cost-effectiveness are established.
Did NOT guarantee NHS funding or widespread access.
Maintained strict controls and made prescribing exclusive to specialists with expertise in certain areas.

In other words, legal prescribing became possible—but NHS funding and broad clinician comfort remain hurdles.

NHS Funding vs. Legal Prescribing: Why Legal Access ≠ NHS Funding

A common misconception is that if a medicine is legal to prescribe, the NHS will pay for it. This is not true. The NHS follows detailed guidance from the National Institute for Health and Care Excellence (NICE) and other advisory bodies before routinely funding any treatment.

For illicit market vs medical cannabis cannabis-based products, despite their legal status:

NHS England has been cautious and restrictive in approving funding.
Most cannabis-based medicines remain unlicensed medicines when used for many indications.
Unlicensed medicines carry slightly higher regulatory uncertainty, which makes NHS organisations hesitant to fund them routinely.

This means that even if a patient is prescribed medical cannabis legally, in many cases they must either pay privately or try to access NHS funding through individual funding requests (IFRs), which can be a complex, lengthy, and often unsuccessful process.

https://bizzmarkblog.com/which-conditions-does-the-nhs-actually-fund-medical-cannabis-for/

Specialist-Only Prescribing Rules: What They Mean for Patients

Currently, medical cannabis prescribing is limited to specialist doctors — typically those working in neurology, pain medicine, or palliative care. General practitioners (GPs) are not permitted to initiate cannabis-based treatments.

This specialist-only rule reflects the limited robust evidence base and the need for expert risk management. However, it also creates practical barriers for patients:

Long waiting lists and limited clinic availability.
Geographic disparities—access depends heavily on local specialist services.
High demand at some private clinics listed on sites such as medicalcannabis.co.uk, where patients pay out of pocket.

Patients often report that accessing specialists willing to prescribe cannabis on the NHS can be challenging, even when they experience benefits from self-medication or private prescriptions.

Unlicensed Cannabis-Based Medicines and NHS Caution

Much of what’s being prescribed under the “medical cannabis” umbrella is not a licensed medicine, meaning it has not gone through the full licensing process considered standard for UK medicines regulation. Examples include some cannabis flower oils or extracts that are compounded products rather than officially authorised drugs.

The NHS is generally cautious about unlicensed medicines because:

They lack large high-quality clinical trial data accepted by regulators like the MHRA.
There can be variation in composition and quality between batches or manufacturers.
Unlicensed status leads to less clear guidance on dosing, side effects, and long-term safety.

This caution aligns with the fundamental principle of “do no harm” and explains why NHS clinicians remain hesitant despite strong patient-reported outcomes cannabis use.

What About the Evidence Base for Medical Cannabis on the NHS?

The evidence base for medical cannabis is evolving but remains limited and condition-specific. NICE and other expert bodies review trials looking at conditions such as:

Chronic neuropathic pain
Spasticity related to multiple sclerosis
Some rare seizure conditions

The quality of trials varies, and while some patients report meaningful benefits, regulators highlight the need for larger, long-term studies to understand effectiveness and risks better. This measured approach is why the NHS is described as cautious prescribing medical cannabis.

If you want to understand how evidence translates into practical prescribing decisions, resources like Releaf’s explainer offer an accessible overview.

Are Patients Imagining Benefits From Cannabis?

Short answer: No. The NHS does not broadly dismiss patient-reported benefits from cannabis. Many specialists recognise anecdotal improvements in symptom management and quality of life. The tension lies in the evidence standard required for national funding and clinician confidence.

To put it simply: patients consistently reporting benefits are driving ongoing research and considerations around access, but NHS prescribing remains cautious because medical cannabis is not yet a fully licensed, well-defined treatment with standard dosing and safety data.

This gap fuels frustration among patients who feel their lived experience is overlooked, but it also reflects the NHS’s obligation to balance innovation with patient safety and equitable use of limited resources.

What Does This Mean for Patients Considering Medical Cannabis?

Be informed: Visit reputable sites like medicalcannabis.co.uk for clinic information and releaf.co.uk for evidence summaries.
Speak to a specialist: Only certain medical specialists can prescribe safely and legally on the NHS.
Understand funding limitations: Even if prescribed, NHS funding is rare; many pay privately.
Consider clinical trials: If suitable, joining trials helps build the evidence base that may improve future access.

Pricing and Private Access: What Patients Can Expect

No single standard NHS price for medical cannabis exists because most prescribing is on a case-by-case basis or private. Prices on private clinics, often listed on medicalcannabis.co.uk, vary widely depending on the formulation and dosing.

If official prices are referenced in future sources, they should be quoted exactly and attributed. For now, prospective patients should be prepared for substantial costs if they pursue private prescriptions.

Summary

The 2018 rescheduling made cannabis-based prescriptions legal but did not guarantee NHS access or funding.
NHS prescribing remains limited to specialists due to cautious assessment of evidence and safety.
Many cannabis-based medicines remain unlicensed, prompting NHS caution.
Patient-reported benefits are real but not yet supported by the kind of evidence NHS requires for routine funding.
Private prescribing fills some gaps but is costly and not a panacea.

In short, the NHS does not think patients are imagining benefits from cannabis—but it does insist on proper evidence before turning those experiences into routine, funded treatments.